Clinical trial
Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer
NCT03573960 is registered in ClinicalTrials.gov with Eisai Pharmaceuticals India Pvt. Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer
- Lead sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 1, 2018
- Completion date
- September 4, 2025
- Enrollment
- 50 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.